Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.

5 Two phase III randomized clinical trials in newly diagnosed and recurrent GBM (Intellance I and Intellance II, respectively) showed a trend toward activity, but failed to demonstrate a significant clinical benefit. 6 , 7 Further preclinical studies demonstrated that limited distribution across the BBB was a major factor limiting the efficacy of systemically administered Depatux-M and that artificial disruption of the BBB or direct, int

also in 53,322 other papers